Lund University is celebrating 350 years. Read more on lunduniversity.lu.se

Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.

Author:
  • Oscar Braun
  • Besim Bico
  • Uzma Chaudhry
  • Henrik Wagner
  • Sasha Koul
  • Patrik Tydén
  • Fredrik Scherstén
  • Stefan Jovinge
  • Peter Svensson
  • Gustav Smith
  • Jesper vanderPals
Publishing year: 2015
Language: English
Pages: 26-30
Publication/Series: Thrombosis Research
Volume: 135
Issue: 1
Document type: Journal article
Publisher: Elsevier

Abstract english

Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin). However, there are uncertainties regarding the risk for thrombosis since poor-responsiveness to clopidogrel is common. Ticagrelor is a more potent platelet inhibitor, but data supporting concurrent use of ticagrelor and warfarin (dual antithrombotic therapy, DT) is limited. This study therefore sought to evaluate the risk of bleeding and thrombosis associated with DT after an acute coronary syndrome (ACS).

Keywords

  • Cardiac and Cardiovascular Systems

Other

Published
  • Cardio-vascular Epidemiology
  • Clinical Coagulation, Malmö
  • Arrhytmias and Cardiac Device treatment
  • Molecular Cardiology
  • ISSN: 1879-2472
E-mail: oscar.braun [at] med.lu.se

Physician

Cardiology

+46 46 17 36 90

32

Project manager

Heart Failure and Mechanical Support

+46 46 17 36 90

32

Research project participant

Molecular Epidemiology and Cardiology

32

Lund University Diabetes Centre, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00